CAP taps Wagner

Jeff Byers | | Health Exec | Precision Medicine

The College of American Pathologists (CAP) has hired Charles Wagner as vice president of its STS (SNOMED Terminology Solutions) division. Wagner will lead CAP STS’ professional services expansion in the health IT marketplace.

In his new position, Wagner will help the Northfield, Ill.-based CAP STS build new services targeted to CAP members and lead business development in the health IT community. These initiatives will also help support the CAP’s transformation efforts under way to foster new roles for pathologists as critical members of the patient care team.

Prior to joining CAP STS, Wagner was managing director of U.S. Healthcare Operations and Global Healthcare Application Delivery at Dell Services, CAP stated.

Jeff Byers

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.